Wall Street brokerages expect BRAINSWAY LTD/S (NASDAQ:BWAY) to report ($0.12) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for BRAINSWAY LTD/S’s earnings. The firm is expected to report its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that BRAINSWAY LTD/S will report full-year earnings of ($0.52) per share for the current financial year, with EPS estimates ranging from ($0.53) to ($0.51). For the next year, analysts expect that the firm will post earnings of ($0.40) per share, with EPS estimates ranging from ($0.49) to ($0.34). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that follow BRAINSWAY LTD/S.
BRAINSWAY LTD/S (NASDAQ:BWAY) last issued its quarterly earnings results on Monday, November 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01. The business had revenue of $5.93 million during the quarter, compared to analyst estimates of $5.75 million.
NASDAQ:BWAY traded up $0.03 during mid-day trading on Friday, reaching $11.55. The company’s stock had a trading volume of 2,580 shares, compared to its average volume of 11,544. The company’s fifty day simple moving average is $11.55 and its two-hundred day simple moving average is $10.08. BRAINSWAY LTD/S has a twelve month low of $8.00 and a twelve month high of $12.53.
An institutional investor recently bought a new position in BRAINSWAY LTD/S stock. Phoenix Holdings Ltd. acquired a new position in BRAINSWAY LTD/S (NASDAQ:BWAY) during the third quarter, according to its most recent 13F filing with the SEC. The firm acquired 310,000 shares of the company’s stock, valued at approximately $2,694,000. Phoenix Holdings Ltd. owned 2.87% of BRAINSWAY LTD/S at the end of the most recent reporting period. Institutional investors and hedge funds own 12.48% of the company’s stock.
BRAINSWAY LTD/S Company Profile
Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.
Featured Article: How does a security become overbought?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BRAINSWAY LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRAINSWAY LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.